Adjunctive Therapies in Parkinson Disease-Have We Made Meaningful Progress?

Affiliations

¹ Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Norman Fixel Institute for Neurological Diseases, University of Florida Health, Gainesville.

Editorial

Tanya Simuni et al. JAMA Neurol. 2022.

. 2022 Feb 1;79(2):119-120.

doi: 10.1001/jamaneurol.2021.4140.

¹ Parkinson's Disease and Movement Disorders Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Norman Fixel Institute for Neurological Diseases, University of Florida Health, Gainesville.

No abstract available

Comment on

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, Gray A, Jenkinson C, McIntosh E, Wheatley K, Williams A, Clarke CE; PD MED Collaborative Group. Gray R, et al. JAMA Neurol. 2022 Feb 1;79(2):131-140. doi: 10.1001/jamaneurol.2021.4736. JAMA Neurol. 2022. PMID: 34962574 Free PMC article. Clinical Trial.